

# ORE PHARMACEUTICAL HOLDINGS INC. (ORXE)

## 25-NSE

Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Filed on 04/05/2010



THOMSON REUTERS

Westlaw<sup>®</sup> BUSINESS

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 25**  
**NOTIFICATION OF REMOVAL FROM LISTING AND/OR**  
**REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES**  
**EXCHANGE ACT OF 1934.**

Commission File Number 000-23317

Issuer: ORE PHARMACEUTICAL HOLDINGS INC.  
Exchange: NASDAQ Stock Market LLC

---

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: One Main Street, Suite 300  
Cambridge,  
MASSACHUSETTS  
02142

Telephone number: 617-649-2001

---

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

---

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)  
 17 CFR 240.12d2-2(a)(2)  
 17 CFR 240.12d2-2(a)(3)  
 17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. <sup>1</sup>

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, NASDAQ Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2010-04-01

Date

By Amy Horton

Name

Associate General Counsel

Title

<sup>1</sup> Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Delisting Determination, The Nasdaq Stock Market, LLC,  
April 1, 2010, Ore Pharmaceutical Holdings Inc. The Nasdaq  
Stock Market, Inc. (the Exchange) has determined to remove from  
listing the common stock of Ore Pharmaceutical Holdings Inc.  
(the Company), effective at the opening of the  
trading session on April 12, 2010. Based on a review of  
the information provided by the Company, Nasdaq Staff  
determined that the Company no longer qualified for  
listing on the Exchange pursuant to Listing Rule  
5550(a)(2). The Company was notified  
of the Staff's determination on March 16, 2010.  
The Company did not appeal the Staff determination  
to the Hearings Panel, and the Staff determination to  
delist the Company became final on March 25, 2010.